Profile: Mead Johnson Nutrition Co (MJN)
24 Oct 2014
Mead Johnson Nutrition Company (Mead Johnson), incorporated on December 17, 2008, is a global pediatric nutrition company. The Company manufactures, distributes and sells infant formulas, children's nutrition and other nutritional products. Its Enfa family of brands, including Enfamil infant formula, is the global brand franchise in pediatric nutrition. Its product portfolio addresses a range of nutritional needs for infants, children and expectant and nursing mothers. The Company markets its portfolio of more than 70 products to mothers, health care professionals and retailers in more than 50 countries in Asia, North America, Latin America and Europe. During the year ended December 31, 2011, it operated two segments: Asia/Latin America and North America/Europe, which consisted of 66% and 34%, respectively, of its net sales. In addition to the Enfa family of brands, the Company markets several other brands on a local, regional or global basis. These brands complement the Enfa family of brands portfolio, such as Nutramigen or the nutritional needs of broad consumer populations, such as ChocoMilk and Cal-C-Tose.
During 2011, the two principal product categories in which the Company operate are infant formula and children's nutrition, which represented 59% and 38% of its net sales. The Enfa family of brands includes infant formula and children's nutrition brands. The Enfa family of brands features infant formula products that include docosahexaenoic acid (DHA) and arachidonic (ARA) to support brain, visual and nervous and immune system development. During2011, its Enfa family of brands were accounted for 80% of its net sales. Its pediatric nutrition products are grouped by category of feeding: infant formula products, children’s nutrition products and other products. During 2011, infant formula, children's nutrition and other product sales consisted approximately 59%, 38% and 3% of its net sales.
The Company’s infant formula products include formulas for routine feeding, solutions formulas for mild intolerance and specialty formula products, including formulas for severe intolerance, formulas for premature and low birth weight infants and medical nutrition products. It designs routine infant formula as a breast milk substitute for healthy, full-term infants without special nutritional needs both for use as the infant's sole source of nutrition and as a supplement to breastfeeding. It also provides products within its routine formula line for healthy full-term infants who experience common feeding problems with symptoms, such as mild spit-up, fussiness or gas. Its routine infant formula has the four main components: protein from cow's milk that is processed to have a profile similar to human milk; a blend of vegetable fats (including DHA/ARA) to replace bovine milk fat in order to better resemble the composition of human milk; a carbohydrate lactose from cow's milk, and a vitamin and mineral micronutrient pre-mix that is blended into the product to meet the specific needs of the infant at a given age.
The Company markets the same product under different names in different regions. Its Stage 1 infant formulas containing DHA and ARA are sold under the brands Enfamil Premium and Enfamil Premium Newborn in the United States. Outside the United States, Enfamil Premium is sold under the brands Enfamil A+ and Enfalac A+. In parts of Asia, Latin America and Europe, it uses the name Enfapro for its Stage 2 products. Its product is milk-based powder, but it produces several infant formulas in ready-to-use and concentrated liquid form for sale primarily in the United States and Canada. During 2011, routine infant formula products consisted of 68% of its infant formula net sales. The Company designs solutions infant formulas to address common feeding tolerance problems in normal infants, including spit-up, fussiness, gas and lactose intolerance. The Company markets its solutions infant formulas for mild intolerance, such as Gentlease and Prosobee under the Enfa family of brands name. During 2011, solutions infant formula products consisted of 18% of its infant formula net sales. Its specialty infant formulas include formulas for severe intolerance, formulas for premature and low birth weight infants and medical nutrition products. During 2011, specialty infant formula products consisted of 14% of its infant formula net sales.
The Company has designed Nutramigen infant formula for use by infants with severe cow’s milk protein allergies. Nutramigen with LGG infant formula is a variant of Nutramigen it markets in Europe and the United States. It also designs products for premature and low birth weight infants. It has designed Enfamil Human Milk Fortifier product as a supplement to a mother's breast milk that improves nutritional density. EnfaCare infant formula, another of its products, is a hypercaloric formula. In addition, Enfamil Premature is an infant formula used primarily in the hospital. It also produces medical foods, or foods for special medical purposes, for nutritional management of individuals with inborn errors of metabolism, such as maple syrup urine disease (Mead Johnson BCAD) and phenylketonuria (Mead Johnson Phenyl-Free). Category 1 products are intended for infants and young children from zero to three years of age and Category 2 products are suitable for children and adults. It produces approximately 20 formulas targeted at specific disorders. It markets these medical nutrition products under the Mead Johnson brand name.
Children's Nutrition Products
The Company’s children's nutrition products are designed to provide children with enhanced nutrition. Its children's nutrition business is in Asia and Latin America. The Company separates its children's nutrition products into two categories: Enfa branded children's nutrition products and other children's nutrition products. The Company markets children's nutrition products under the Enfa family of brands. It designs these products to meet the changing nutrition needs of children at different stages of development. It offers products at Stages three, four and five that are designed for children's nutritional needs at one to three years of age, three to five years of age and beyond five years of age, respectively. These products are not breast milk substitutes and are not designed for use as the sole source of nutrition but instead are designed to be a part of a child's appropriate diet. Its use of the Enfa prefix allows for a consistent equity across Stages three, four and five, with products, such as Enfagrow offered at Stage three and Enfakid offered at Stage four and EnfaSchool at Stage five. Enfa branded children's nutrition products comprised 71% of its children's nutrition products sales during the years ended December 31, 2011.
The Company produces a range of other products, including pre-natal and post-natal nutritional supplements for expectant and nursing mothers, including Expecta LIPIL and EnfaMama A+. Its products for nursing mothers provide the developing fetus or breastfed infant with vitamin supplements and/or an increased supply of DHA for brain, visual and nervous system development. These products also supplement the mother's diet by providing either DHA or ARA with increased proteins, as well as 24 vitamins and minerals. Its pediatric vitamin products, such as Enfamil Poly-Vi-Sol, provide a range of benefits for infants, including multivitamins and iron supplements. During 2011, these other products consisted of 3% of its net sales.
The Company competes with Abbott Laboratories, Danone, Nestle S.A. and Pfizer Inc.
Mead Johnson Nutrition Co
2701 PATRIOT BOULEVARD
GLENVIEW IL 60026-8039